Dogwood Therapeutics, Inc.
DWTX Nasdaq
SEC CIK 1818844
Follow Dogwood Therapeutics
Weekly email: filings, results
Revenue, last quarter
$100K
Net income
−$4.9M
+69% vs same quarter last year
EPS, diluted
−$0.14
+98.3% vs same quarter last year
Operating cash flow
−$4.6M
−41.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$34.3M |
| FY24 | −$12.3M |
| FY23 | −$5.3M |
| FY22 | −$12.2M |
| FY21 | −$16M |
| FY20 | −$10.3M |
| FY19 | - |